[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470014":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":40,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":25,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Comparator : Test group","EXPERIMENTAL","AD-218",[13],"Drug: AD-218",{"label":15,"type":16,"description":17,"interventionNames":18},"Active Comparator : Control group","ACTIVE_COMPARATOR","AD-218A",[19],"Drug: AD-218A",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","PO, Once daily(QD), 12weeks",[9],null,{"type":22,"name":17,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Kyu Chang Won, M.D., Ph.D","Yeungnam University Hospital","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Sarah Yoon","CONTACT","82-031-891-5576","sryoon@addpharma.co.kr",{"name":30,"role":36,"phone":25,"phoneExt":25,"email":25},[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":25,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Yeongnam University Hospital","RECRUITING","Daegu","Nam-gu","42415","South Korea",{"type":49,"coordinates":50},"Point",[51,52],128.59111,35.87028,{"lat":52,"lon":51},[55],{"name":30,"role":36,"phone":25,"phoneExt":25,"email":25},{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100470014","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-ad-218-100470014",false,"NCT05400317","A Study to Evaluate the Efficacy and Safety of AD-218","A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia","Inclusion Criteria:\n\n* A man or woman over 19 years old.\n* Sign on ICF prior to study participation\n\nExclusion Criteria:\n\n* History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)\n* Other exclusions applied","ALL","19 Years",{"count":68,"type":69},520,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of AD-218",[75],"Mixed Dyslipidemia","2025-02-03",{"date":78,"type":79},"2025-02-05","ACTUAL",{"date":81,"type":79},"2022-07-27",{"date":83,"type":69},"2026-06-30",{"name":5,"class":6},1]